Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 27:11:604967.
doi: 10.3389/fimmu.2020.604967. eCollection 2020.

Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors

Affiliations
Review

Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors

Violena Pietrobon et al. Front Immunol. .

Abstract

In recent years, cancer immunotherapy experienced remarkable developments and it is nowadays considered a promising therapeutic frontier against many types of cancer, especially hematological malignancies. However, in most types of solid tumors, immunotherapy efficacy is modest, partly because of the limited accessibility of lymphocytes to the tumor core. This immune exclusion is mediated by a variety of physical, functional and dynamic barriers, which play a role in shaping the immune infiltrate in the tumor microenvironment. At present there is no unified and integrated understanding about the role played by different postulated models of immune exclusion in human solid tumors. Systematically mapping immune landscapes or "topographies" in cancers of different histology is of pivotal importance to characterize spatial and temporal distribution of lymphocytes in the tumor microenvironment, providing insights into mechanisms of immune exclusion. Spatially mapping immune cells also provides quantitative information, which could be informative in clinical settings, for example for the discovery of new biomarkers that could guide the design of patient-specific immunotherapies. In this review, we aim to summarize current standard and next generation approaches to define Cancer Immune Topographies based on published studies and propose future perspectives.

Keywords: deep learning; imaging techniques; immune exclusion; immune topography; single-cell analysis; solid tumors.

PubMed Disclaimer

Conflict of interest statement

VP and FM were employed by the company Refuge Biotechnologies. AC was employed by ESSA Pharmaceuticals. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Immune topographies of cancer. (A–C) First-order immune topographies. (D–F) Second-order immune topographies.
Figure 2
Figure 2
Spatial transcriptomics workflow including the downstream analysis. (A) Histological tumor sections are annotated by a pathologist and sections of interest are stained with hematoxylin and eosin before permeabilization. (B) The sections are placed on glass slides containing RT-primers arrayed as spots that correspond to tissues domains. The RT-primers at each spot have a unique spatial ID barcode, which is sequenced along with the transcript to enable trace-back to a specific tissue domain. (C, D) After sequencing, gene expression profiles and factor activity maps are created.
Figure 3
Figure 3
Example of spatial transcriptomic analysis on three prostate cancer biopsies: histology and gene expression factors (257). (A) Annotated brightfield images of tissue sections of interest, stained with hematoxylin and eosin. (B) Factor activity maps for morphological features (normal glands, PIN glands, stroma and cancer cells) and for inflamed regions (reactive stroma, immune profile).
Figure 4
Figure 4
Example of NICHE-seq, assessing the cellular composition of defined niches (215). (A) Two-photon laser scanning microscopy (TPLSM) images of naïve inguinal lymph nodes from PA-GFP host mice before and after photoactivation (green). In red, adoptively transferred cells and cyan marks the T-cell area and the B follicles, respectively. (B) Expression profile from photoactivated B follicles (cyan) or T-cell areas (red). (C) Relative enrichment of different T-cell types [(B), CD4, CD8low, CD8high and CD8 Activated] in each subregion. *p < 0.05.
Figure 5
Figure 5
Intravital two photon imaging of naïve T-cells in lymph nodes (302). (A) 3D reconstruction representing 85 x 120 x 75 μm of the T-cell area. Fluorescently labeled T-cells (green) are observed in the proximity of presumptive high endothelial venules (red), identified by i.v. injection of tetramethylrhodamine dextran. Scale bar 30 μm in all axes. (B) Video-rate imaging of a T-cell flowing in a small vessel within a T-cell region of the node. Image is a superposition of nine consecutive video frames and shows progression of a single labeled T-cell traveling at about 0.03 cm/s within a blood vessel. Scale bar 25 μm. Copyright (2003) National Academy of Sciences, U.S.A.
Figure 6
Figure 6
Protein-based scaffolds for targeting cell antigens in vivo.

Similar articles

Cited by

References

    1. Guo ZS. The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer). BMC Cancer (2018) 18:1086. 10.1186/s12885-018-5020-3 - DOI - PMC - PubMed
    1. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 371:1507–17. 10.1056/NEJMoa1407222 - DOI - PMC - PubMed
    1. Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L. Trial Watch: Adoptively transferred cells for anticancer immunotherapy. Oncoimmunology (2017) 6:e1363139. 10.1080/2162402X.2017.1363139 - DOI - PMC - PubMed
    1. Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci (2019) 15:2548–60. 10.7150/ijbs.34213 - DOI - PMC - PubMed
    1. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 118:4817–28. 10.1182/blood-2011-04-348540 - DOI - PMC - PubMed

Substances